NPH/Reg — Competitive Intelligence Brief

NPH/Reg (NPH/Reg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin combination therapy. Area: Diabetes.

marketed Insulin combination therapy Insulin receptor Diabetes Small molecule

Target snapshot

NPH/Reg (NPH/Reg) — Tehran University of Medical Sciences. NPH/Reg is a combination insulin therapy that provides both intermediate-acting (NPH) and rapid-acting (Regular) insulin to control blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NPH/Reg TARGET	NPH/Reg	Tehran University of Medical Sciences	marketed	Insulin combination therapy	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin combination therapy class)

1. Eli Lilly and Company · 3 drugs in this class
2. Hospital Universitario San Ignacio · 1 drug in this class
3. Peking University People's Hospital · 1 drug in this class
4. Riverside University Health System Medical Center · 1 drug in this class
5. Tehran University of Medical Sciences · 1 drug in this class
6. Université NAZI BONI · 1 drug in this class